COMP <GO>
MRNA vs AMGN // EV/EBITDA & P/E VALUATION
Moderna Inc. (NASDAQ) VS. Amgen Inc. (NASDAQ) • 15-METRIC TALLY: MRNA 2
— AMGN 11
■ METRIC PARITY
LAST: $221.72 (-0.47%) • MKT CAP: $88.93B
valuation
—
LAST: $466.01 (+1.15%) • MKT CAP: $249.09B
valuation
27.2x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MRNA VS. AMGN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MRNA | AMGN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 55.30% | 67.20% | -11.90 | AMGN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -34.10% | 14.50% | -48.60 | AMGN | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 27.2x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.32% | 3.25% | -5.57 | AMGN | /fcf-yield <GO> |
| Operating Margin | -60.00% | 24.70% | -84.70 | AMGN | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 21.00% | -81.00 | AMGN | /net-margins <GO> |
| Revenue Growth (YoY) | -39.90% | 10.00% | -49.90 | AMGN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.06% | -2.06 | AMGN | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 15.07 | 3.83 | +11.24 | MRNA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | AMGN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.7 | 67.0 | -9.30 | AMGN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.10 | 0.87 | +0.23 | MRNA | /macro-sensitivity <GO> |
| Forward P/E Multiple | 32.0x | 30.0x | +2.00 | AMGN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $88.93B | $249.09B | -$160.15B | AMGN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MRNA REV | AMGN REV | MRNA GROSS % | AMGN GROSS % | MRNA FCF | AMGN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.94B | $36.75B | 55.3% | 67.2% | -$2.06B | $8.10B |
| FY 2024 | $3.24B | $33.42B | 54.8% | 61.5% | -$4.05B | $10.39B |
| FY 2023 | $6.85B | $28.19B | — | — | -$3.43B | $7.20B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MRNA // BETA 1.10
AMGN // BETA 0.87